Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund IX, L.P.(14.5%),ARCH Venture Fund IX Overage, L.P.(14.5%), etc.

SEC · Feb 15 04:24

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund IX, L.P.(14.5%),ARCH Venture Fund IX Overage, L.P.(14.5%), etc.

Risk Disclaimer